All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 166 points (-1.0%) at 16,455 as of Tuesday, Feb. 23, 2016, 11:55 AM ET. The NYSE advances/declines ratio sits at 990 issues advancing vs. 1,939 declining with 142 unchanged.

The Drugs industry currently sits down 1.5% versus the S&P 500, which is down 0.9%. Top gainers within the industry include

Valeant Pharmaceuticals International

(

VRX

), up 8.2%,

Perrigo

(

PRGO

), up 2.0% and

Mylan

(

MYL

), up 1.4%. On the negative front, top decliners within the industry include

PTC Therapeutics

(

PTCT

), down 50.8%,

Jazz Pharmaceuticals

(

JAZZ

), down 3.2%,

Incyte

(

INCY

), down 3.0%,

Vertex Pharmaceuticals

(

VRTX

), down 2.5% and

Shire

(

SHPG

), down 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Novo Nordisk A/S

(

NVO

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novo Nordisk A/S is up $0.41 (0.8%) to $52.01 on heavy volume. Thus far, 1.3 million shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $51.91-$52.38 after having opened the day at $52.33 as compared to the previous trading day's close of $51.60.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $132.4 billion and is part of the health care sector. Shares are down 11.2% year-to-date as of the close of trading on Monday. Currently there are 2 analysts who rate Novo Nordisk A/S a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Novo Nordisk A/S

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Novo Nordisk A/S Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Eli Lilly and

(

LLY

) is up $0.87 (1.2%) to $73.88 on light volume. Thus far, 1.5 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.9 million shares. The stock has ranged in price between $73.06-$74.37 after having opened the day at $73.23 as compared to the previous trading day's close of $73.01.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $80.5 billion and is part of the health care sector. Shares are down 13.3% year-to-date as of the close of trading on Monday. Currently there are 9 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Eli Lilly and

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, expanding profit margins, increase in net income and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Eli Lilly and Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Teva Pharmaceutical Industries

(

TEVA

) is up $0.73 (1.3%) to $58.15 on light volume. Thus far, 2.2 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 6.4 million shares. The stock has ranged in price between $57.12-$58.27 after having opened the day at $57.13 as compared to the previous trading day's close of $57.42.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. Teva Pharmaceutical Industries has a market cap of $51.4 billion and is part of the health care sector. Shares are down 12.5% year-to-date as of the close of trading on Monday. Currently there are 14 analysts who rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Teva Pharmaceutical Industries

as a

buy

. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Teva Pharmaceutical Industries Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).